imiquimod has been researched along with Allergic Encephalomyelitis in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hawiger, D; Hsueh, EC; Li, L; Liu, X; Luo, H; Opejin, A; Peng, G; Wang, T; Wang, Y; Ye, J | 1 |
| Blackshear, PJ; Curtis, AD; Flake, GP; Hill, GD; Lai, WS; Mannie, MD; Patial, S; Stumpo, DJ | 1 |
| Fitzgerald, D; Gran, B; O'Brien, K; Rostami, A | 1 |
3 other study(ies) available for imiquimod and Allergic Encephalomyelitis
| Article | Year |
|---|---|
TLR7 Signaling Regulates Th17 Cells and Autoimmunity: Novel Potential for Autoimmune Therapy.
Topics: Aminoquinolines; Animals; Autoimmunity; Cell Differentiation; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Humans; Imiquimod; Immunotherapy; Inflammation; Interleukin-17; Membrane Glycoproteins; Mice; Signal Transduction; STAT3 Transcription Factor; Suppressor of Cytokine Signaling Proteins; Th1 Cells; Th17 Cells; Toll-Like Receptor 7 | 2017 |
Enhanced stability of tristetraprolin mRNA protects mice against immune-mediated inflammatory pathologies.
Topics: Aminoquinolines; Animals; Arthritis, Experimental; Cells, Cultured; Collagen; Dermatitis; Encephalomyelitis, Autoimmune, Experimental; Imiquimod; Inflammation; Mice; Mice, Transgenic; Mutation; RNA, Messenger; Tristetraprolin | 2016 |
The TLR7 agonist, imiquimod, increases IFN-beta production and reduces the severity of experimental autoimmune encephalomyelitis.
Topics: Adjuvants, Immunologic; Aminoquinolines; Animals; Cell Proliferation; Dose-Response Relationship, Drug; Encephalomyelitis, Autoimmune, Experimental; Female; Imiquimod; Interferon-beta; Leukocytes, Mononuclear; Mice; Mice, Inbred C57BL; Mice, Knockout; Receptor, Interferon alpha-beta; RNA, Messenger; Severity of Illness Index; Statistics, Nonparametric; T-Lymphocytes | 2010 |